Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herombopag for Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer
NCT06745219Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hetrombopag in Thrombocytopenia, sponsored by Peking University Cancer Hospital & Institute. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
hetrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT06745219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06745219.